Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly [ADP-ribose] polymerase 15 (PARP15) is a member of the PARP family of proteins, which modify target proteins by ADP-ribosylation, a reversible post-translational modification using NAD+ as a substrate[1][2][4]. PARP15 is characterized by the presence of a macro domain and catalyzes mono-ADP-ribosylation (not poly)[2][4]. Its physiological functions are poorly understood, but PARP15 is grouped within the “macro-PARP” subfamily (alongside PARP9 and PARP14), suggesting possible regulatory roles in transcription and immune signaling, as well as associations with cancer development or prognosis[2][4]. Structural and inhibitor studies exist, but no clinically approved drugs are specific for PARP15, and its role as a pharmacological target remains mostly exploratory[3][2][4].
Inhibition of mono-ADP-ribosylation activity; Modulation of apoptosis (inferred from inhibitor studies in cells)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly [ADP-ribose] polymerase 15 (PARP15).